AustinPx

AustinPx is a client-centric CDMO founded in 2007, based in Georgetown, Texas. The company offers preclinical through Phase II formulation and process development services, along with cGMP manufacturing of oral dosage forms. Core capabilities include bioavailability enhancement, dose form development, and speed-to-clinic strategies.

The company is the inventor of KinetiSol™ Technology, a next-generation amorphous solid dispersion (ASD) platform designed for poorly soluble active pharmaceutical ingredients. KinetiSol offers a smaller footprint, broader design space, and greener processing solutions compared to conventional ASD approaches. AustinPx can supply KinetiSol drug product intermediates (DPI) through commercial manufacturing.

AustinPx's approach is data-driven and technology-agnostic, tailoring formulation strategies based on the unique physicochemical characteristics of each molecule and client objectives. The company emphasizes flexibility and responsiveness in early-stage development, adapting to shifting timelines and changing clinical targets. Services span preclinical development, formulation development, analytical testing, and GMP manufacturing, with cGMP facilities capable of supporting preclinical testing, GLP toxicology studies, and Phase I/II clinical trials.